FMTX   $20.01  0.10% Market Closed

Forma Therapeutics Holdings Inc
Last Events:

2022-10-12 Signal in Stochastic changed from bearish recovery to bullish. The stochastic indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: main and signal line crossing.

2022-10-08 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.

2022-10-07 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.

2022-10-07 Signal in Stochastic changed from bearish weakening to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2022-10-06 Trend pattern changed from канал to расходящийся клин с наклоном вверх.

2022-10-06 Signal in Stochastic changed from bearish recovery to bearish weakening. The stochastic indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: main and signal line crossing.

2022-10-05 Trend pattern changed from расходящийся клин с наклоном вверх to канал.

2022-10-05 Signal in Stochastic changed from bullish reversal to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: main and signal line crossing.


Current temperature: 0.27
ST: 0, Cor:

50-50 Year Forecast
Low with 50% probability: 14.73
Target: 21.00
High with 50% probability: 25.54
Analyst Recommendations:
Number of estimates 3
Target Price Mean 21.00
Mean unverified/preliminary 21.00 / 21.00
Target Price Low / High 20.00 / 23.00
Median / STD DEV 20.00 / 1.73
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total - Sell Sell
rsi ActivelyBuy Sell Sell
macd - - Sell
stoch - Sell Sell
ma20 - - -
ma50 - - -
ma100 - - -
Candlestick PatternOct. 13, 2022 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US34633R1041
ceo Mr. Frank D. Lee
Website https://www.formatherapeutics.com
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.